Showing results (31-40 of 48) with videos related to
Sort By:
Pageof 5
Postepy Dermatologii I Alergologii|July 20, 2019
Polish Society of Allergology statement on the diagnosis and treatment of severe, difficult-to-control bronchial asthmaMaciej Kupczyk, Zbigniew Bartuzi, Anna Bodzenta-Łukaszyk, et al.Clinical and Experimental Immunology|May 25, 2021
Chronic bacterial pulmonary infections in advanced cystic fibrosis differently affect the level of sputum neutrophil elastase, IL-8 and IL-6Grzegorz Majka, Henryk Mazurek, Magdalena Strus, et al.Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|February 4, 2005
[Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part I. Mechanisms of actions and clinical effectiveness of treatment in children with asthma]Małgorzta Bartkowiak-Emeryk, Anna Breborowicz, Andrzej Emeryk, et al.Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego|February 4, 2005
[Effectiveness and safety of fluticasone propionate in therapy of children suffering from asthma. Part II. Safety aspects of therapy with fluticasone propionate in asthmatic children]Małgorzta Bartkowiak-Emeryk, Anna Breborowicz, Andrzej Emeryk, et al.Paediatric Drugs|June 1, 2007
A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter studyAlexander Chuchalin, Eszter Csiszér, Kàlmàn Gyurkovics, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|September 5, 2020
Aerosolized lancovutide in adolescents (≥12 years) and adults with cystic fibrosis - a randomized trialErnst Eber, Maria Trawinska-Bartnicka, Dorota Sands, et al.Pediatric Pulmonology|January 28, 2014
Long-term efficacy and safety of aerosolized tobramycin 300 mg/4 ml in cystic fibrosisHenryk Mazurek, Raphaël Chiron, Tereza Kucerova, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|February 19, 2025
AI-facilitated home monitoring for cystic fibrosis exacerbations across pediatric and adult populationsHenryk Mazurek, Andrzej Emeryk, Kamil Janeczek, et al.Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|October 4, 2020
Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosisJames F Chmiel, Patrick Flume, Damian G Downey, et al.The Lancet. Respiratory Medicine|September 3, 2023
Safety and efficacy of the epithelial sodium channel blocker idrevloride in people with primary ciliary dyskinesia (CLEAN-PCD): a multinational, phase 2, randomised, double-blind, placebo-controlled crossover trialFelix C Ringshausen, Adam J Shapiro, Kim G Nielsen, et al.Pageof 5